Perfect Day was a rising cellular agriculture company specializing in lab-based milk. Its founders had created and patented a formula for an ingredient that could produce authentic-tasting non-dairy products. At the beginning of 2020, the US-based firm received US$140 million in funding, and the founders had to navigate a complex operating and stakeholder environment to map out a growth strategy. The complex situation required them to answer related questions that were easy to understand but difficult to answer. First, the founders would have to chart the expected evolution of the lab-based milk industry as it moved to the full roll-out of products. The founders would next have to decide on Perfect Day’s positioning in its changing industry. Finally, they would have to assess the myriad players, both as stakeholders and as potential alliance partners, in order to support the strategic positioning decision.

Perfect Day was a rising cellular agriculture company specializing in lab-based milk. Its founders had created and patented a formula for an ingredient that could produce authentic-tasting non-dairy products. At the beginning of 2020, the US-based firm received US$140 million in funding, and the founders had to navigate a complex operating and stakeholder environment to map out a growth strategy. The complex situation required them to answer related questions that were easy to understand but difficult to answer. First, the founders would have to chart the expected evolution of the lab-based milk industry as it moved to the full roll-out of products. The founders would next have to decide on Perfect Day's positioning in its changing industry. Finally, they would have to assess the myriad players, both as stakeholders and as potential alliance partners, in order to support the strategic positioning decision.

Tetra Bio-Pharma (Tetra) was a new firm operating in a murky but promising industry—cannabinoid-derived pharmaceutical products. But, the firm had been so involved in navigating drug development and approval processes that it had lost track of its identity. The firm did not define itself initially, and with its rapid growth, shifting strategies, evolving competencies, and plethora of alliances, Tetra needed a stronger focus. Adding to the turmoil, the firm was operating within the rapidly changing global marijuana industry—essentially, uncharted waters. Given that the firm’s new drugs were about to receive government approval, the firm had to determine how to build its brand.

Tetra Bio-Pharma (Tetra) was a new firm operating in a murky but promising industry-cannabinoid-derived pharmaceutical products. But, the firm had been so involved in navigating drug development and approval processes that it had lost track of its identity. The firm did not define itself initially, and with its rapid growth, shifting strategies, evolving competencies, and plethora of alliances, Tetra needed a stronger focus. Adding to the turmoil, the firm was operating within the rapidly changing global marijuana industry-essentially, uncharted waters. Given that the firm's new drugs were about to receive government approval, the firm had to determine how to build its brand.

Managers must reconsider their preconceptions about conglomerates, or multi-industry firms as they are now often called, because today's examples have much to teach us about successful corporate strategy. We examined the strategies of the largest conglomerates that have, for a sustained period, practiced the form. Four archetypes are available to managers for adding value to a broad portfolio of businesses. In top-performing firms, the bewildering diversity of end products can blind the casual observer to the intense focus of headquarters and the tight cohesion among the head office, the businesses, and the environment.